Gritstone Bio Inc. (NASDAQ: GRTS) stock plunged by 3.9% at last close whereas the GRTS stock price rises by 5.29% in the after-hours trading session. Gritstone Bio is basically a medical biotechnology business which is working on next-generation immunotherapies for a variety of cancers and infectious disorders.
GRTS stock’ Significant Update
The first participant in a Phase 1 experiment has been dosed, according to Gritstone bio, Inc. The purpose of the experiment is to see how effective GRT-R910, a self-amplifying mRNA (SAM) second generation SARS-CoV-2 vaccine, is. The vaccine aims to improve and broaden the immunogenicity of first-generation COVID-19 vaccinations in people aged 60 and up. The University of Manchester and Manchester University NHS Foundation Trust in the United Kingdom are collaborating on this single-center study.
Gritstone’s CORAL programme includes the GRT-R910. It’s a second-generation COVID-19 vaccination technology that delivers a broad collection of antigens against SARS-CoV-2 using a SAM vector built with lipid nanoparticles. This contains both stable spike proteins and viral protein sections. It contains highly conserved T cell epitopes. Increased duration and amount of antigen synthesis with SAM vaccines may allow for lower vaccine doses and obviate the necessity of repeat administrations due to self-amplification. It also has the ability to elicit powerful, long-lasting, and widespread immune responses across all SARS-CoV-2 variants in a safe manner.
Moreover,
Professor Andrew Ustianowski will be the local lead investigator for this study. He is known as the Clinical Lead for the NIHR COVID Vaccine Research Programme, Consultant in Infectious Diseases and Tropical Medicine at North Manchester General Hospital (part of MFT), and Honorary Clinical Chair at The University of Manchester. Professor Ustianowski is the study’s Chief Investigator, and MFT is the primary site.
Andrew Allen, co-founder, president and CEO of Gritstone stated that,
The SAM COVID vaccine generates strong CD8+ T cell responses. Also it has powerful neutralising antibody responses. It also promises longer-lasting immunity, especially in groups that are more vulnerable. GRT-R910 is developed in a way that it has extensive therapeutic benefits against a variety of SARS-CoV-2 subtypes. For this, GRT-R910 produces exceptional conserved viral proteins that may be less susceptible to antigenic drift.
